Loading…
Holista LLC dba HolistaPet was cited for marketing unapproved new animal drugs, specifically multiple CBD-containing products for dogs, cats, and horses (including CBD oils, treats, chews, pellets, and capsules) without FDA approval. The FDA determined these products violated the Federal Food, Drug, and Cosmetic Act by being unsafe under Section 512(a) and adulterated under Section 501(a)(5), as the company made therapeutic claims on its website www.holistapet.com and social media platforms (Instagram and Pinterest) that established the products as drugs intended for animal use. The company was prohibited from introducing or delivering these unapproved products into interstate commerce under Section 301(a) of the FD&C Act.